TP53 Status and Response to Chemotherapy in Breast Cancer
Open Access
- 1 June 2008
- journal article
- review article
- Published by S. Karger AG in Pathobiology
- Vol. 75 (2) , 132-139
Abstract
Despite its central role in the control of apoptosis, senescence and cell cycle arrest, the tumor suppressor protein p53 remains an enigma for its possible role in predicting response to chemotherapy in cancer patients. Many studies remained inconclusive, others showed a better response for tumors with normal p53, and some recent studies showed adverse effects of normal p53 for response to treatment. p53 is not only a powerful pro-apoptotic factor in response to drug-induced DNA damages but also a potential inducer of cell cycle arrest, protecting tumor cells from further cytotoxic damages. Our review describes the classical as well as the more recent concepts. In order to draw definite conclusions, future works should use more reliable methods to assess the TP53 status and should address more homogeneous tumor subpopulations treated with homogeneous chemotherapy regimens.Keywords
This publication has 55 references indexed in Scilit:
- The use of an in vitro adenosine triphosphate-based chemotherapy response assay to predict chemotherapeutic response in breast cancerThe Breast, 2008
- Shaping Genetic Alterations in Human Cancer: The p53 Mutation ParadigmCancer Cell, 2007
- Cellular Senescence in Cancer and AgingCell, 2007
- Impact of mutant p53 functional properties onTP53mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 databaseHuman Mutation, 2007
- The transcriptional targets of p53 in apoptosis controlBiochemical and Biophysical Research Communications, 2005
- Meta-analysis of the role of p53 status in isogenic systems tested for sensitivity to cytotoxic antineoplastic drugsBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2004
- A mutant TP53 gene status is associated with a poor prognosis and anthracycline-resistance in breast cancer patientsEuropean Journal of Cancer, 2003
- P53 is the strongest predictor of survival in high‐risk primary breast cancer patients undergoing high‐dose chemotherapy with autologous blood stem cell supportInternational Journal of Cancer, 2002
- Prediction of chemotherapeutic response by collagen gel droplet embedded culture‐drug sensitivity test in human breast cancersInternational Journal of Cancer, 2002
- Comparison between p53 protein measurements using the luminometric immunoassay and immunohistochemistry with detection ofp53 gene mutations using cDNA sequencing in human breast tumorsInternational Journal of Cancer, 1998